HAVCR2 and cancer: As cancer cells can upregulate alternative checkpoints, such as TIM-3 or LAG-3, aptamers targeting a single checkpoint (e.g., PD-L1/PD-1) may not be sufficient to overcome immune evasion mechanisms [101].